In this clinical topic video, medical oncologist Prof. Laurence Albiges shares her perspective on the challenges related to treating nccRCC, the emergence of combination treatments, guideline recommendations, and the importance of shared decision-making with patients. 

Prof. Albiges reviews data from key trials linked to recommendations from the NCCN and ESMO guidelines and discusses the heterogeneous nature of nccRCC and the diverse histological subtypes, along with the importance of correct diagnosis to ensure treatment regimens are individualised based on the relevant histological subtype. 

Watch the video and download the accompanying slide set for more details.

Clinical takeaways

• Non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous disease that encompasses a diverse subset of histological subtypes
• Large prospective studies relevant to a single histology of nccRCC have been limited, and treatment options have been scarce
• Treatment regimens should be individualised based on the histological subtype
  (e.g. papillary, chromophobe, or collecting duct carcinoma), molecular characteristics, and the presence of metastases but more data is needed to determine optimal treatment according to these features
• In the absence of clinical trial availability, tyrosine kinase inhibitors (TKIs) and immune checkpoint blockade combinations may be prescribed for metastatic disease; multiple trials of these agents are ongoing